Trial Profile

Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Pegaspargase (Primary) ; Rivoceranib (Primary)
Indications Extranodal NK-T-cell lymphoma; Gastrointestinal cancer
Focus Therapeutic Use

Most Recent Events

15 Jun 2023 Results (As of cut off date Jan 31 2023, n=44) assessing the efficacy and safety of camrelizumab in combination of low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II NK/TCL presented at the 28th Congress of the European Haematology Association
29 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com